A Phase 4 interventional study of Fingolimod in Relapsing Remitting Multiple Sclerosis RRMS, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-03-02.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 25th largest by enrollment, is one of 4 that started in 2012, is one of 17 in phase 4, and was the 23rd registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 42nd largest by enrollment of the 64 interventional ones that give a count, is one of 7 that started in 2012, is one of 26 in phase 4, and was the 35th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
This was a 3-year, prospective, multi-center, open-label study to describe the long term changes of optical coherence tomography (OCT) parameters in RRMS patients under treatment with Fingolimod. It was designed to longitudinally study the degeneration of retinal axons by measuring change in RNFL thickness by latest OCT-technology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients eligible for inclusion in this study have to fulfill all of the following criteria:
Exclusion Criteria
Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
Patients who have been treated with:
Patients with any of the following cardiovascular conditions :
history or presence of severe myopia
chronic systemic corticosteroids [>30 consecutive days; doses higher than Cushing threshold e.g. prednisone 7.5mg/d], intraocular anti-angiogenic drugs [ranibizumab, bevacizumab], intraocular steroids etc.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No study drug was provided. Fingolimod was to be prescribed according to local label. The decision to prescribe fingolimod had to be made independent of this study.
Drug: Fingolimod
All subjects received an oral dose of 0.5 mg fingolimod (FTY720) per capsule (hard gelatin capsules) once daily according to local label for the treatment of their MS.
Also known as: FTY720
Change From Baseline to Month 36 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)
The primary endpoint was the change, i.e. the absolute difference, in average RNFL thickness from baseline to month 36 (or last values in case of missing data) in the Full Analysis Set (FAS). Average RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT).
Time frame: Baseline, month 36
Change From Baseline to Month 12 and 24 in Average Retinal Nerve Fiber Layer Thickness (RNFLT)
Change from baseline in average RNFL thickness to months 12 and 24 (or last values in case of missing data) in the Full Analysis Set (FAS). Average RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT).
Time frame: Baseline, month 12, month 24
Change From Baseline to Month 12, 24 and 36 in Average Quadrant Retinal Nerve Fiber Layer Thickness (RNFLT)
Change from baseline in average quadrant RNFL thickness to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS). Average quadrant RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT). Quadrant RNFL thickness were: Nasal-inferior; nasal-superior; temporal-inferior; temporal-superior.
Time frame: Baseline, month 12, month 24, month 36
Change From Baseline to Month 12, 24 and 36 in Total Macular Volume (TMV)
Change from baseline in TMV to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS).
Time frame: 12, 24 and 36 months
Change From Baseline to Month 12, 24 and 36 in Ganglion Cell Inner Plexiform (GCIP)
Change from baseline in GCIP to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS). The change in Ganglion cell layer thickness (GCLT) had been defined as secondary endpoint in the protocol, but OCT measured the GCIP instead. This was done because both layers were not clearly separable by OCT. GCIP was calculated as mean of the inner sectors (nasal, superior, temporal, and inferior) and declared as usual parameter instead. This change was introduced prior to data base lock, but the derivation of GCIP was corrected after data base lock.
Time frame: Baseline, month 12, month 24, month 36
Number of Participants With Adverse Events
Number of participants with adverse events and specifically macular edema.
Time frame: 36 months
Subjects were screened at 10 study centers in Germany (9 centers) and Switzerland (1 center).
| Milestone | Fingolimod - Longitudinal Assessment |
|---|---|
| Started | 87 |
| Completed | 60 |
| Not completed | 27 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Administrative problems | 2 |
| Withdrew: Unsatisfactory therapeutic effect | 3 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Abnormal test procedure result(s) | 4 |
| Withdrew: Abnormal laboratory value(s) | 4 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Adverse event | 5 |
The primary endpoint was the change, i.e. the absolute difference, in average RNFL thickness from baseline to month 36 (or last values in case of missing data) in the Full Analysis Set (FAS). Average RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT).
| micrometer | Fingolimod - Longitudinal Assessment |
|---|---|
| Change From Baseline to Month 36 in Average Retinal Nerve Fiber Layer Thickness (RNFLT) | -1.5 ± 2.7 |
Change from baseline in average RNFL thickness to months 12 and 24 (or last values in case of missing data) in the Full Analysis Set (FAS). Average RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT).
| micrometer | Fingolimod - Longitudinal Assessment |
|---|---|
| Change from baseline to month 12 | -0.8 ± 2.4 |
| Change from baseline to month 24 | -1.1 ± 2.4 |
Change from baseline in average quadrant RNFL thickness to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS). Average quadrant RNFL thickness was the average of valid measurements of the right and left eye and assessed by optical coherence tomography (OCT). Quadrant RNFL thickness were: Nasal-inferior; nasal-superior; temporal-inferior; temporal-superior.
| micrometer | Fingolimod - Longitudinal Assessment |
|---|---|
| Nasal-superior RNFL thickness: month 12 | 0.5 ± 4.0 |
| Nasal-superior RNFL thickness: month 24 | -0.4 ± 3.4 |
| Nasal-superior RNFL thickness: month 36 | -0.7 ± 3.9 |
| Nasal-inferior RNFL thickness: month 12 | -1.2 ± 4.9 |
| Nasal-inferior RNFL thickness: month 24 | -1.6 ± 5.1 |
| Nasal-inferior RNFL thickness: month 36 | -2.1 ± 5.2 |
| Temporal-inferior RNFL thickness: month 12 | -1.2 ± 2.5 |
| Temporal-inferior RNFL thickness: month 24 | -1.6 ± 3.1 |
| Temporal-inferior RNFL thickness: month 36 | -2.3 ± 4.1 |
| Temporal-superior RNFL thickness: month 12 | -0.5 ± 3.9 |
| Temporal-superior RNFL thickness: month 24 | -0.4 ± 3.4 |
| Temporal-superior RNFL thickness: month 36 | -1.1 ± 4.1 |
Change from baseline in TMV to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS).
| Cubic millimeter | Fingolimod - Longitudinal Assessment |
|---|---|
| Change from baseline to month 12 | -0.03 ± 0.08 |
| Change from baseline to month 24 | -0.04 ± 0.08 |
| Change from baseline to month 36 | -0.06 ± 0.10 |
Change from baseline in GCIP to months 12, 24 and 36 (or last values in case of missing data) in the Full Analysis Set (FAS). The change in Ganglion cell layer thickness (GCLT) had been defined as secondary endpoint in the protocol, but OCT measured the GCIP instead. This was done because both layers were not clearly separable by OCT. GCIP was calculated as mean of the inner sectors (nasal, superior, temporal, and inferior) and declared as usual parameter instead. This change was introduced prior to data base lock, but the derivation of GCIP was corrected after data base lock.
| micrometer | Fingolimod - Longitudinal Assessment |
|---|---|
| Change from baseline to month 12 | -0.49 ± 2.39 |
| Change from baseline to month 24 | -0.42 ± 2.74 |
| Change from baseline to month 36 | -0.46 ± 3.01 |
Number of participants with adverse events and specifically macular edema.
| Participants | Fingolimod - Longitudinal Assessment |
|---|---|
| No. of subjects with any AE | 80 |
| No. of subjects with macular edema | 0 |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment up to maximum duration of 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod - Longitudinal Assessment | 0/87 (0%) | 11/87 (12.6%) | 68/87 (78.2%) |
| Event | Fingolimod - Longitudinal Assessment |
|---|---|
| MULTIPLE SCLEROSIS RELAPSENervous system disorders | 2/87 |
| AORTIC VALVE INCOMPETENCECardiac disorders | 1/87 |
| ERYSIPELASInfections and infestations | 1/87 |
| GASTROENTERITIS VIRALInfections and infestations | 1/87 |
| OPHTHALMIC HERPES ZOSTERInfections and infestations | 1/87 |
| WOUND INFECTIONInfections and infestations | 1/87 |
| LOWER LIMB FRACTUREInjury, poisoning and procedural complications | 1/87 |
| RADIUS FRACTUREInjury, poisoning and procedural complications | 1/87 |
| SUTURE RELATED COMPLICATIONInjury, poisoning and procedural complications | 1/87 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 1/87 |
| Event | Fingolimod - Longitudinal Assessment |
|---|---|
| NASOPHARYNGITISInfections and infestations | 41/87 |
| MULTIPLE SCLEROSIS RELAPSENervous system disorders | 21/87 |
| HYPERTENSIONVascular disorders | 12/87 |
| HEADACHENervous system disorders | 10/87 |
| LYMPHOPENIABlood and lymphatic system disorders | 9/87 |
| VITAMIN D DEFICIENCYMetabolism and nutrition disorders | 8/87 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 7/87 |
| URINARY TRACT INFECTIONInfections and infestations | 7/87 |
| BACK PAINMusculoskeletal and connective tissue disorders | 7/87 |
| DIARRHOEAGastrointestinal disorders | 6/87 |
| Age, Continuous(Years) | Fingolimod - Longitudinal Assessment |
|---|---|
| Mean | 35.9 ± 9.5 |
| Sex: Female, Male(Participants) | Fingolimod - Longitudinal Assessment |
|---|---|
| Female | 55 |
| Male | 32 |
| Race/Ethnicity, Customized(Participants) | Fingolimod - Longitudinal Assessment |
|---|---|
| Caucasian | 84 |
| Other | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
Ran from Aug 2012 to primary completion in Feb 2019, 77 months.
Results were first posted in Mar 2020, 1 year after primary completion.
Of 36 industry-sponsored phase 4 interventional studies under Multiple Sclerosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 37. This study's 77 months is above that.
Counting every sponsor, half of 69 studies reached it within 34 months; a quarter within 23 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod